Ucb Pharma, S.a.

Ucb Biopharma Sprl

Biogen Ma Inc.

Ucbbiopharma Srl

Marc Roger De Ryck

Alastair David Griffiths Lawson

Terence Seward Baker

Helene Margaret Finney

Karen Margrete Miller

Christian Gilbert J Wolff

Margaret S Lee

Rafal Kaminski

Sharon Tamir

Benoit Kenda

Karine Leclercq

Alastair David Lawson

Christian Gilbert Wolff

The invention generally relates to the use of nuclear transport modulators, e.g., CRM1 inhibitors, of Formula (I) for treating epilepsy in a subject. Subjects can have unprovoked seizures without prior warning that affect one or both hemispheres of the brain. The disclosed methods can reduce the severity and occurrence of these unprovoked epileptic seizures and can result in resolution of epilepsy. The method comprises administering to the subject an effective amount of a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof. 

CRM1 inhibitors for treating epilepsy

A Na1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Na1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.

[object Object]

An anti-E1 ion channel antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.

Method of treating a patient for pain by administering an anti-ion channel antibody

Antibodies to the E1 extracellular loop of ion channels

Function modifying NAv 1.7 antibodies

Growing community of inventors

Brussels, Belgium

Marc Roger De Ryck